Physician profile
John Ha
NPI 1457733008
$22,202.56
in general payments reported to CMS, 2019-2025
43 companies · $3,041 in 2025
The $3,041 reported for 2025 was more than what 89% of Pain Medicine (Anesthesiology) providers received nationally (typical 2025 total: $458).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,442 · 2020: $561 · 2021: $3,611 · 2022: $3,129 · 2023: $5,895 · 2024: $3,525 · 2025: $3,041.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Travel and Lodging: $1,522 · Consulting Fee: $325.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,613.88 |
| Travel and Lodging | $1,522.08 |
| Consulting Fee | $325.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nevro Corp. | $4,980.50 | 2019-2024 | Senza |
| Abbott Laboratories | $4,027.86 | 2021-2025 | Proclaim, Eterna, Ionicrf |
| Saluda Medical Americas, INC. | $2,786.32 | 2022-2025 | Evoke Scs, Evoke |
| Boston Scientific Corporation | $1,780.38 | 2019-2025 | General - Pain Management, Wavewriter Alpha Prime 16, Intracept |
| Collegium Pharmaceutical, INC. | $955.04 | 2020-2025 | Belbuca, Xtampza, Nucynta |
| Biotronik Nro, INC. | $940.37 | 2023-2025 | Prospera, Biotronik |
| Medtronic, INC. | $873.28 | 2021-2025 | Intellis Adaptivestim, Inceptiv, Vanta Adaptivestim |
| Abbvie INC. | $779.77 | 2021-2025 | |
| Pacira Pharmaceuticals Incorporated | $681.74 | 2022-2025 | Iovera, Zilretta |
| Medtronic USA, INC. | $441.94 | 2019 | |
| Amgen INC. | $386.47 | 2021-2023 | Evenity, Prolia |
| Pfizer INC. | $370.14 | 2023-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $349.62 | 2020-2025 | Relistor |
| Globus Medical, INC. | $317.73 | 2025 | Senza, Vyrsa V1 |
| Biohaven Pharmaceutical Holding Company Ltd. | $284.96 | 2022 |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fidia Pharma USA INC. | $265.87 | 2020-2025 | Triluron, Hymovis, Hyalgan |
| Trevena, INC. | $238.28 | 2022-2023 | Olinvyk |
| Avanos Medical | $231.57 | 2021-2024 | Trivisc Sodium Hyaluronate, Genvisc 850 Sodium Hyaluronate, Generator |
| Almatica Pharma LLC | $208.25 | 2021-2023 | Gralise |
| Si-Bone, INC. | $195.12 | 2020-2025 | |
| Biodelivery Sciences International, INC. | $162.55 | 2020-2021 | |
| Vertos Medical, INC. | $128.84 | 2023 | Mild Device Kit |
| Stryker Corporation | $102.47 | 2020-2025 | |
| Biohaven Pharmaceuticals, INC. | $100.05 | 2020-2021 | |
| Nalu Medical, INC. | $73.29 | 2022-2025 | Nalu Neurostimulation System |
| Lilly USA, LLC | $68.40 | 2022-2023 | Emgality, Reyvow |
| Scilex Pharmaceuticals INC. | $63.09 | 2025 | |
| Vertex Pharmaceuticals Incorporated | $61.09 | 2024-2025 | |
| Horizon Therapeutics Plc | $47.29 | 2021-2022 | |
| Impel Pharmaceuticals INC. | $42.77 | 2022-2023 | Trudhesa |
| Relievant Medsystems, INC. | $32.23 | 2021-2022 | |
| Kowa Pharmaceuticals America, INC. | $28.59 | 2023 | Seglentis |
| Teva Pharmaceuticals USA, INC. | $26.94 | 2021 | |
| Depuy Synthes Sales INC. | $25.99 | 2022 | |
| Pacira Therapeutics, INC. | $24.72 | 2020-2021 | |
| Lundbeck LLC | $23.36 | 2022 | |
| Xeris Pharmaceuticals, INC. | $16.77 | 2023 | Keveyis |
| Vibrant Gastro, INC. | $15.82 | 2024 | Vibrant Starter Kit |
| Sanofi-Aventis U.S. LLC | $13.79 | 2023 | |
| Spr Therapeutics, INC | $13.20 | 2021 | |
| Allergan, INC. | $12.56 | 2020 | |
| Athena Bioscience, LLC | $11.82 | 2022 | |
| Grt US Holding, INC. | $11.72 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Ha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.